Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06433661 · ClinicalTrials.gov registry record · Phase 1
A Research Study of the Effect of Food on Etavopivat in Healthy Participants
A Phase 1 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT06433661 is a Phase 1 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 16 participants.
The verdict
NCT06433661, a Phase 1 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of food on the amount of etavopivat in the bloodstream of healthy participants. Participants will take a single oral dose of etavopivat following a high-fat meal (i.e. fed) and on an empty stomach (i.e fasted) on two separate occasions.The study will last up to 50 days (including screening).
Interventions
- DRUG Etavopivat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2024-05-28 |
| Est. Completion | 2024-07-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06433661
The ClinicalTrials.gov registry entry for NCT06433661 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Etavopivat is the first listed.
NCT06433661 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06433661 about?
NCT06433661 is a clinical study titled "A Research Study of the Effect of Food on Etavopivat in Healthy Participants". The purpose of this study is to evaluate the effect of food on the amount of etavopivat in the bloodstream of healthy participants. Participants will take a single oral dose of etavopivat following a high-fat meal (i.e. fed) and on an empty stomach (i.e fasted) on two separate occasions.The study wi...
What is the current status of trial NCT06433661?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2024-05-28. Estimated completion is 2024-07-08.
What interventions are being tested in trial NCT06433661?
The interventions under investigation include: Etavopivat (DRUG).
Who is sponsoring clinical trial NCT06433661?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.